Michael Lilly to Prostatic Neoplasms, Castration-Resistant
This is a "connection" page, showing publications Michael Lilly has written about Prostatic Neoplasms, Castration-Resistant.
Connection Strength
2.351
-
Elevated serum CEA is associated with liver metastasis and distinctive circulating tumor DNA alterations in patients with castration-resistant prostate cancer. Prostate. 2022 09; 82(13):1264-1272.
Score: 0.800
-
Circulating tumor DNA alterations in patients with metastatic castration-resistant prostate cancer. Cancer. 2019 05 01; 125(9):1459-1469.
Score: 0.629
-
A phase II trial of dasatinib in patients with metastatic castration-resistant prostate cancer treated previously with chemotherapy. Anticancer Drugs. 2013 Aug; 24(7):743-53.
Score: 0.431
-
A phase II study of docetaxel plus lycopene in metastatic castrate resistant prostate cancer. Biomed Pharmacother. 2021 Nov; 143:112226.
Score: 0.190
-
Circulating-tumor DNA as predictor of enzalutamide response post-abiraterone treatment in metastatic castration-resistant prostate cancer. Cancer Treat Res Commun. 2020; 24:100193.
Score: 0.175
-
The Sphingosine Kinase 2 Inhibitor ABC294640 Reduces the Growth of Prostate Cancer Cells and Results in Accumulation of Dihydroceramides In Vitro and In Vivo. Mol Cancer Ther. 2015 Dec; 14(12):2744-52.
Score: 0.126